medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-33-34-36medalphabet-3508Research ArticleСтатьиБиохимические аспекты патогенеза мигрениBiochemical aspects of migraine pathogenesishttps://orcid.org/0000-0002-3276-7615БолдыреваЮ. В.BoldyrevaYu. V.

Болдырева Юлия Викторовна, к. м. н., доцент, доцент кафедры биологической химии Института фармации

г. Тюмень

Boldyreva Yulia V., PhD Med, associate professor, associate professor at Dept of Biological Chemistry of the Institute of Pharmac

Tyumen

tgma.06@mail.ruhttps://orcid.org/0000-0001-5405-7182ЛебедевИ. А.LebedevI. A.

Лебедев Илья Аркадьевич, д. м. н., проф. кафедры топографической анатомии и оперативной хирургии с курсом остеопатии Института клинической медицины

г. Тюмень

Lebedev Ilya A., DM Sci (habil.), professor at Dept of Topographic Anatomy of the Institute of Clinical Medicine

Tyumen

https://orcid.org/0000-0002-1736-4084СуплотовС. Н.SuplotovS. N.

Суплотов Сергей Николаевич, д. м. н., проф., зав. кафедрой клинической лабораторной диагностики Института клинической медицины

г. Тюмень

Suplotov Sergey N., DM Sci (habil.), professor, head of Dept of Clinical Laboratory Diagnostics of the Institute of Clinical Medicine

Tyumen

https://orcid.org/0009-0005-6760-9923БажинаМ. В.BazhinaM. V.

Бажина Мария Владимировна, ординатор I года обучения

г. Тюмень

Bazhina Maria V., first-year resident

Tyumen

https://orcid.org/0000-0002-7534-9552ГавриленкоЕ. А.GavrilenkoE. A.

Гавриленко Елена Александровна, студентка IV курса Института материнства и детства

г. Тюмень

Gavrilenko Elena A., 4th year student of the Institute of Motherhood and Childhood

Tyumen

https://orcid.org/0000-0001-7450-2888СенатороваО. В.SenatorovO. V.

Сенаторова Ольга Владимировна, к. м. н., доцент кафедры детских болезней с курсом поликлинической педиатрии Института материнства и детства

г. Тюмень

Senatorova Olga V., PhD Med, associate professor at Dept of Childhood Diseases with a course in outpatient pediatrics at the Institute of Motherhood and Childhood

Tyumen

ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава РоссииРоссияTyumen State Medical UniversityRussian Federation202319012024033Неврология и психиатрия (4)3436Copyright © Болдырева Ю.В., Лебедев И.А., Суплотов С.Н., Бажина М.В., Гавриленко Е.А., Сенаторова О.В., 20242024Болдырева Ю.В., Лебедев И.А., Суплотов С.Н., Бажина М.В., Гавриленко Е.А., Сенаторова О.В.Boldyreva Y.V., Lebedev I.A., Suplotov S.N., Bazhina M.V., Gavrilenko E.A., Senatorov O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3508

В статье приведен анализ современных источников литературы, посвященных биохимическим аспектам патогенеза мигрени. Описана роль тригеминоваскулярной системы и роль биологически активных веществ, вовлеченных в этот процесс. Понимание описанных механизмов позволит улучшить продолжительность и качество жизни пациентов.

The article provides an analysis of modern literature sources devoted to the biochemical aspects of the pathogenesis of migraine. The role of the trigeminovascular system, etc. is described. biologically active substances involved in this process. Understanding the described processes makes it possible to increase the duration and quality of life of patients.

мигреньбиохимияпатогенезголовная больтригеминоваскулярная системанейротрансмиттерынейромедиаторынейропептидыmigrainebiochemistrypathogenesisheadachetrigeminovascular systemneurotransmittersneuropeptidesReferencesAshina M., Migraine N., Engl J. Med. 2020 Nov 5; 383 (19): 1866–1876. https://doi.org/10.1056/nejmra1915327. PMID: 33211930.Ashina M., Migraine N., Engl J. Med. 2020 Nov 5; 383 (19): 1866–1876. https://doi.org/10.1056/nejmra1915327. PMID: 33211930.Moskowitz M. A. The neurobiology of vascular head pain. Ann Neurol 16 (2): 157–168. https://doi.org/10.1002/ana.410160202Moskowitz M. A. The neurobiology of vascular head pain. Ann Neurol 16 (2): 157–168. https://doi.org/10.1002/ana.410160202Ashina M., Hansen J. M., Do T. P., Melo-Carrillo A., Burstein R., Moskowitz M. A. Migraine and the trigeminovascular system – 40 years and counting. Lancet Neurol 18 (8): 795–804. https://doi.org/10.1016/s1474–4422(19)30185–1Ashina M., Hansen J. M., Do T. P., Melo-Carrillo A., Burstein R., Moskowitz M. A. Migraine and the trigeminovascular system – 40 years and counting. Lancet Neurol 18 (8): 795–804. https://doi.org/10.1016/s1474–4422(19)30185–1Ashina M., Terwindt G. M., Al-Karagholi MA-M et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397 (10283): 1496–1504. https://doi.org/10.1016/S0140–6736(20)32162–0Ashina M., Terwindt G. M., Al-Karagholi MA-M et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397 (10283): 1496–1504. https://doi.org/10.1016/S0140–6736(20)32162–0Del Fiacco M., Quartu M., Boi M., Serra M. P., Melis T., Boccaletti R. et al. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. J Neurol Neurosurg Psychiatry. (2015) 86: 393–7. DOI: 10.1136/jnnp‑2014–308813.Del Fiacco M., Quartu M., Boi M., Serra M. P., Melis T., Boccaletti R. et al. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. J Neurol Neurosurg Psychiatry. (2015) 86: 393–7. DOI: 10.1136/jnnp‑2014–308813.Su M., Yu S. Chronic migraine: A process of dysmodulation and sensitization. Mol Pain. (2018) 14: 1–10. DOI: 10.1177/1744806918767697.Su M., Yu S. Chronic migraine: A process of dysmodulation and sensitization. Mol Pain. (2018) 14: 1–10. DOI: 10.1177/1744806918767697.Agostoni E. C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F. et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. J Headache Pain. (2019) 20: 1–9. DOI: 10.1186/s10194–019–1038–4.Agostoni E. C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F. et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. J Headache Pain. (2019) 20: 1–9. DOI: 10.1186/s10194–019–1038–4.Cernuda-Morollón E., Martínez-Camblor P., Ramón C., Larrosa D., Serrano-Pertierra E., Pascual J. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. (2014) 54: 987–95. DOI: 10.1111/head.12372.Cernuda-Morollón E., Martínez-Camblor P., Ramón C., Larrosa D., Serrano-Pertierra E., Pascual J. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. (2014) 54: 987–95. DOI: 10.1111/head.12372.Shimizu T., Shibata M., Toriumi H., Iwashita T., Funakubo M., Sato H. et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis. (2012) 48: 367–78. DOI: 10.1016/j.nbd.2012.07.010.Shimizu T., Shibata M., Toriumi H., Iwashita T., Funakubo M., Sato H. et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis. (2012) 48: 367–78. DOI: 10.1016/j.nbd.2012.07.010.Кондратьева Н. С. Характеристика молекулярно-генетических маркеров патогенеза мигрени. Диссертационная работа на соискание ученой степени кандидата биологических наук по специальности. 2016. Т. 3.Kondratyeva N. S. Characteristics of molecular genetic markers of migraine pathogenesis. Dissertation for the degree of candidate of biological sciences in the specialty. 2016. T. 3.Cernuda-Morollón E., Larrosa D., Ramón C., Vega J., Martínez-Camblor P., Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. (2013) 81: 1191–6. DOI: 10.1212/wnl.0b013e3182a6cb72.Cernuda-Morollón E., Larrosa D., Ramón C., Vega J., Martínez-Camblor P., Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. (2013) 81: 1191–6. DOI: 10.1212/wnl.0b013e3182a6cb72.Cernuda-Morollón E., Martínez-Camblor P., Alvarez R., Larrosa D., Ramón C., Pascual J. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. (2015) 35: 310–6. DOI: 10.1177/0333102414535111.Cernuda-Morollón E., Martínez-Camblor P., Alvarez R., Larrosa D., Ramón C., Pascual J. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. (2015) 35: 310–6. DOI: 10.1177/0333102414535111.Filippi M., Messina R. The chronic migraine brain: What have we learned from neuroimaging? Front Neurol. (2019) 10: 1–10. DOI: 10.3389/fneur.2019.01356.Filippi M., Messina R. The chronic migraine brain: What have we learned from neuroimaging? Front Neurol. (2019) 10: 1–10. DOI: 10.3389/fneur.2019.01356.Pérez-Pereda S., Toriello-Suárez M., Ocejo-Vinyals G., Guiral-Foz S., Castillo-Obeso J., Montes-Gómez S. et al. Serum CGRP, VIP, and PACAP usefulness in migraine: A case-control study in chronic migraine patients in real clinical practice. Mol Biol Rep. (2020) 47: 7125–38. DOI: 10.1007/s11033–020–05781–0.Pérez-Pereda S., Toriello-Suárez M., Ocejo-Vinyals G., Guiral-Foz S., Castillo-Obeso J., Montes-Gómez S. et al. Serum CGRP, VIP, and PACAP usefulness in migraine: A case-control study in chronic migraine patients in real clinical practice. Mol Biol Rep. (2020) 47: 7125–38. DOI: 10.1007/s11033–020–05781–0.Edvinsson L., Juul R., Jansen I. Perivascular neuropeptides (NPY, VIP, CGRP and SP) in human brain vessels after subarachnoid haemorrhage. Acta Neurol Scand. (1994) 90: 324–30. DOI: 10.1111/j.1600–0404.1994.tb02732.x.Edvinsson L., Juul R., Jansen I. Perivascular neuropeptides (NPY, VIP, CGRP and SP) in human brain vessels after subarachnoid haemorrhage. Acta Neurol Scand. (1994) 90: 324–30. DOI: 10.1111/j.1600–0404.1994.tb02732.x.Hirabayashi T., Nakamachi T., Shioda S. Discovery of PACAP and its receptors in the brain. J Headache Pain. (2018) 19: 1–8. DOI: 10.1186/s10194–018–0855–1.Hirabayashi T., Nakamachi T., Shioda S. Discovery of PACAP and its receptors in the brain. J Headache Pain. (2018) 19: 1–8. DOI: 10.1186/s10194–018–0855–1.Ghatei M. A., Takahashi K., Suzuki Y., Gardiner J., Jones P. M., Bloom S. R. Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol. (1993) 136: 159–66. DOI: 10.1677/joe.0.1360159.Ghatei M. A., Takahashi K., Suzuki Y., Gardiner J., Jones P. M., Bloom S. R. Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol. (1993) 136: 159–66. DOI: 10.1677/joe.0.1360159.Amin F. M., Hougaard A., Schytz H. W., Asghar M. S., Lundholm E., Parvaiz A. I. et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide‑38. Brain. (2014) 137: 779–94. DOI: 10.1093/brain/awt369.Amin F. M., Hougaard A., Schytz H. W., Asghar M. S., Lundholm E., Parvaiz A. I. et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide‑38. Brain. (2014) 137: 779–94. DOI: 10.1093/brain/awt369.Rahmann A., Wienecke T., Hansen J. M., Fahrenkrug J., Olesen J., Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. (2008) 28: 226–36. DOI: 10.1111/j.1468–2982.2007.01497.x.Rahmann A., Wienecke T., Hansen J. M., Fahrenkrug J., Olesen J., Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. (2008) 28: 226–36. DOI: 10.1111/j.1468–2982.2007.01497.x.Hansen J. M., Sitarz J., Birk S., Rahmann A. M., Oturai P. S., Fahrenkrug J. et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. (2006) 26: 992–1003. DOI: 10.1111/j.1468–2982.2006.01149.x.Hansen J. M., Sitarz J., Birk S., Rahmann A. M., Oturai P. S., Fahrenkrug J. et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. (2006) 26: 992–1003. DOI: 10.1111/j.1468–2982.2006.01149.x.Markovics A., Kormos V., Gaszner B., Lashgarara A., Szoke E., Sandor K. et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol- induced trigeminovascular activation in mice. Neurobiol Dis. (2012) 45: 633–44. DOI: 10.1016/j.nbd.2011.10.010.Markovics A., Kormos V., Gaszner B., Lashgarara A., Szoke E., Sandor K. et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol- induced trigeminovascular activation in mice. Neurobiol Dis. (2012) 45: 633–44. DOI: 10.1016/j.nbd.2011.10.010.Ploug K. B., Baun M., Hay-Schmidt A., Olesen J., Jansen-Olesen I. Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol. (2010) 637: 109–17. DOI: 10.1016/j.ejphar.2010.03.027.Ploug K. B., Baun M., Hay-Schmidt A., Olesen J., Jansen-Olesen I. Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol. (2010) 637: 109–17. DOI: 10.1016/j.ejphar.2010.03.027.Ploug K. B., Amrutkar D. V., Baun M., Ramachandran R., Iversen A., Lund T. M. et al. K (ATP) channel openers in the trigeminovascular system. Cephalalgia. (2012) 32: 55–65. DOI: 10.1177/0333102411430266.Ploug K. B., Amrutkar D. V., Baun M., Ramachandran R., Iversen A., Lund T. M. et al. K (ATP) channel openers in the trigeminovascular system. Cephalalgia. (2012) 32: 55–65. DOI: 10.1177/0333102411430266.Al-Karagholi M.A., Ghanizada H., Hansen J. M., Skovgaard L. T., Olesen J., Larsson H. B.W. et al. Levcromakalim, an adenosine triphosphate-sensitive potassium channel opener, dilates extracerebral but not cerebral arteries. Headache. (2019) 59: 1468–80. DOI: 10.1111/head.13634.Al-Karagholi M.A., Ghanizada H., Hansen J. M., Skovgaard L. T., Olesen J., Larsson H. B.W. et al. Levcromakalim, an adenosine triphosphate-sensitive potassium channel opener, dilates extracerebral but not cerebral arteries. Headache. (2019) 59: 1468–80. DOI: 10.1111/head.13634.Al-Karagholi M.A., Ghanizada H., Nielsen C. W., Hougaard A., Ashina M. Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain. (2021). DOI: 10.1093/brain/awab136. [Epub ahead of print]Al-Karagholi M.A., Ghanizada H., Nielsen C. W., Hougaard A., Ashina M. Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain. (2021). DOI: 10.1093/brain/awab136. [Epub ahead of print]Al-Karagholi M.A., Hansen J. M., Guo S., Olesen J., Ashina M. Opening of ATP-sensitive potassium channels causes migraine attacks: A new target for the treatment of migraine. Brain. (2019) 142: 2644–54. DOI: 10.1093/brain/awz199.Al-Karagholi M.A., Hansen J. M., Guo S., Olesen J., Ashina M. Opening of ATP-sensitive potassium channels causes migraine attacks: A new target for the treatment of migraine. Brain. (2019) 142: 2644–54. DOI: 10.1093/brain/awz199.Young N. P., Philpot L. M., Vierkant R. A., Rosedahl J. K., Upadhyaya S. G., Harris A. et al. Episodic and chronic migraine in primary care. Headache. (2019) 59: 1042–51. DOI: 10.1111/head.13543.Young N. P., Philpot L. M., Vierkant R. A., Rosedahl J. K., Upadhyaya S. G., Harris A. et al. Episodic and chronic migraine in primary care. Headache. (2019) 59: 1042–51. DOI: 10.1111/head.13543.Diener H. C., Dodick D. W., Goadsby P. J., Lipton R. B., Olesen J., Silberstein S. D. Chronic migraine–classification, characteristics and treatment. Nat Rev Neurol. (2012) 8: 162–71. DOI: 10.1038/nrneurol.2012.13.Diener H. C., Dodick D. W., Goadsby P. J., Lipton R. B., Olesen J., Silberstein S. D. Chronic migraine–classification, characteristics and treatment. Nat Rev Neurol. (2012) 8: 162–71. DOI: 10.1038/nrneurol.2012.13.Кукушкин М. Л. Что является причиной боли при мигрени? Российский журнал боли. 2018 (3): 87–95. https://doi.org.10.25731/rasp.2018.03.023.Kukushkin M. L. What causes migraine pain? Russian Journal of Pain. 2018 (3): 87–95. https://doi.org.10.25731/rasp.2018.03.023.Xu H., Han W., Wang J., Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. The Journal of Headache and Pain 2016; 17: 113–131.Xu H., Han W., Wang J., Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. The Journal of Headache and Pain 2016; 17: 113–131.

The authors declare that there are no conflicts of interest present.